Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook



 

PGD could offer new hope for mitochondrial disease parents

06 June 2011

By Dr Marianne Kennedy

Appeared in BioNews 610

Women at risk of passing on mitochondrial disease to their children could use PGD to give birth to an unaffected child. The scientists at Maastricht University Medical Centre, Netherlands, claim their work has the potential to prevent the transmission of mitochondrial diseases.

Mitochondria are known as the 'power houses' of the cell as they convert the energy contained in food to energy for the cell. They are membrane-enclosed structures inside cells that use their own DNA (mitochondrial DNA - mtDNA) as well as DNA in the cell's nucleus to direct their function. Mutations in mtDNA are varied, and have serious implications. For example, if the mutations do not cause an early death, children may be affected by visual and hearing problems, loss of muscle co-ordination, poor growth, mental retardation, heart, liver and kidney disease, neurological problems, respiratory disorders and dementia.

However, there are two key difficulties in predicting the inheritance of mitochondrial diseases. Firstly, there is a threshold of mutant mtDNA which must be exceeded before clinical symptoms occur. Secondly, the mtDNA mutation level inherited by the children of a female carrier can vary greatly between siblings and even twins.

Prenatal diagnosis cannot be used to predict mitochondrial disease since the mutation load in mtDNA detected in chorionic villus samples does not correlate to future severity of disease. The multinational team from Holland, Australia and the UK therefore decided to investigate whether PGD would be a better alternative. Leader of the study, Dr Debby Hellebrekers said: 'If we could find a minimal level of mtDNA mutation load below which the chance for an embryo of being affected was acceptably low, we could offer PGD to women who otherwise had little chance of giving birth to a healthy child'.

The team studied 327 unrelated patients or families who between them had 159 different disease-causing mtDNA mutations. They measured the amount of mutated mtDNA in muscle tissue – as this correlates best with prenatal tissues - of affected individuals and compared this to their unaffected relatives from their maternal family (because mitochondria are maternally inherited). They found that if less than 18 percent of mtDNA was mutated, that individual had a 95 percent or greater chance of being unaffected.

'Being able to find the minimal level of mutant mtDNA below which the chances of passing on a disorder is low was therefore very important', said Dr Hellebrekers. 'Currently, there are no effective treatments for mtDNA disorders. Although we cannot guarantee that a mutant mtDNA level of 18 percent or lower will result in the birth of an unaffected child, we think that the chances of having a healthy child are high enough to make using PGD in this instance morally acceptable'.

'Our research enables us to give genetic counselling to women at risk with respect to their reproductive choices and to provide them, for the first time, with the opportunity to give birth to a healthy baby. The prevalence of mtDNA disorders is 1 in 5,000, which means that the families of about 146,000 patients in Europe can now have the option of having a healthy child. This is a choice that they do not currently have', she said.

The findings were reported at the European Human Genetics Conference in Amsterdam, May 2011.

SOURCES & REFERENCES
European Human Genetics Conference 2011 | 30 May 2011
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

13 February 2012 - by Professor Mary Herbert 
The advent of PGD extended the scope of IVF beyond the treatment of infertility. PGD is predominantly used to prevent transmission of genetic defects arising from mutations in nuclear DNA. However, it can also be used to reduce the risk of transmitting mutations in mitochondrial DNA (mtDNA), which cause a range of debilitating and life-threatening diseases...
13 February 2012 - by Dr Kristina Elvidge 
Mitochondrial diseases are soon to be brought to the attention of the general public, as the Government seeks to gauge the attitude of the nation towards a ground-breaking IVF treatment that could prevent these conditions being passed from mother to child...
23 January 2012 - by Maria Botcharova 
An experimental genetic technique to prevent serious diseases from passing between mother and child is to receive £5.8 million funding. The Wellcome Trust is contributing £4.4 million to the new Centre for Mitochondrial Research at Newcastle University...
10 October 2011 - by Dr Lux Fatimathas 
US researchers have developed a way to analyse the viability of human eggs at a genetic level without causing them harm. This technology will help improve the chances of successful IVF for couples with fertility problems...
15 August 2011 - by Dr Malcolm Smith 
The Australian state of Victoria was the first common law jurisdiction in the world to enact legislation to regulate assisted reproductive technologies (ARTs). Victoria's legislative framework has been updated a number of times and the most recent legislation (the Assisted Reproductive Treatment Act 2008 (Vic)) came into effect on 1 January 2010...

03 May 2011 - by MacKenna Roberts 
Further research is needed into the safety and effectiveness of techniques to prevent children being born with mitochondrial disease, a Human Fertilisation and Embryology Authority (HFEA) report has concluded...
03 May 2011 - by Professor Alison Murdoch 
Medicine has faced many controversial milestones, none more so than those involving reproduction. The UK Government must now decide whether we can use IVF technology to reduce the risk of transmission of mitochondrial DNA abnormalities. Will they accept it or reject it?...
14 March 2011 - by MacKenna Roberts 
Health Secretary, Andrew Lansley has asked the Human Fertilisation and Embryology Authority (HFEA) to convene an expert group 'to assess the effectiveness and safety' of a fertility treatment that would enable children to be born without potentially devastating, incurable mitochondrial diseases.
01 September 2009 - by Adam Fletcher 
A variation of somatic cell nuclear transfer (SCNT), reported online in the journal Nature, could be used in humans to allow women with a certain group of incurable inherited conditions - known as mitochondrial disorders - to have children without passing on the condition. Because the technique, developed by Dr Shoukhrat Mitalipov and team from the Orgeon National Primate Research Centre, US, involves the the sperm from one monkey and two eggs from different monkeys...
09 June 2008 - by MacKenna Roberts 
The UK Parliament's rejection of an amendment to new fertility legislation could delay the only potential new treatment for a class of roughly 50 devastating inherited metabolic disorders from becoming available for possibly years beyond when the technology is proven safe and effective for clinical use, according...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust
FROZEN ASSETS?
Preserving Sperm, Eggs and Embryos

FREE event
Edinburgh
25 October 2016

BOOK HERE


RETHINKING THE ETHICS OF EMBRYO RESEARCH
Genome Editing, 14 Days and Beyond

Public Conference
London
7 December 2016

Speakers include

Professor Magdalena Zernicka-Goetz

Dr Kathy Niakan

Professor Sir Ian Wilmut

Lord George Carey

Baroness Mary Warnock

Dr Simon Fishel

Professor Bruce Whitelaw

Professor Alison Murdoch

Professor David Jones

Professor Sarah Franklin

Professor Stephen Wilkinson

BOOK HERE

Good Fundraising Code
 
Become a Friend of PET HERE and give the Progress Educational Trust a regular donation